Molecular profiling of docetaxel cytotoxicity in breast cancer cells: Uncoupling of aberrant mitosis and apoptosis

Oncogene

Volumn 26, Issue 20, 2007, Pages 2902-2913

  Hernandez Vargas H ^a   Palacios, J ^a,b   Moreno Bueno, G ^a,c  

^a Structural Biology and Biocomputing Programme   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

Aberrant mitosis; cDNA microarrays; Docetaxel; Mitotic arrest; Taxanes

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DOCETAXEL; PROTEASOME INHIBITOR; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL CYCLE; CELL DEATH; CELL STRAIN MCF 7; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DIPLOIDY; DRUG MECHANISM; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MITOSIS; MITOSIS INHIBITION; PRIORITY JOURNAL; STRUCTURAL GENE; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA; CELL CYCLE; CELL PROLIFERATION; DIPLOIDY; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOSIS; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 34247898998     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210102     Document Type: Article

References (42)

1. Aapro M. (1996). The scientific rationale for developing taxoids. Anticancer Drugs 7(Suppl 2): 33-36.
2. Avramis V, Nandy P, Kwock R, Solorzano M, Mukherjee S, Danenberg P et al. (1998). Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. Anticancer Res 18: 2327-2338.
3. Baker SD, Zhao M, Lee CKK, Verweij J, Zabelina Y, Brahmer JR et al. (2004). Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 10: 1976-1983.
4. Berchem G, Bosseler M, Mine N, Avalosse B. (1999). Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. Anticancer Res 19: 535-540.
5. Blagosklonny MV. (2006). Prolonged mitosis versus tetraploid checkpoint: how p53 measures the duration of mitosis. Cell Cycle 5: 971-975.
6. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z et al. (2002). Histone deacetylase inhibitors all Induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 1: 937-941.
7. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers L. (1996). Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56: 1851-1854.
8. Blajeski AL, Kottke TJ, Kaufmann SH. (2001). A Multistep Model for Paclitaxel-Induced Apoptosis in Human Breast Cancer Cell Lines. Exp Cell Res 270: 277-288.
9. Boudny V, Nakano S. (2002). Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2. Br J Cancer 86: 463-469.
10. Brown I, Shalli K, McDonald S, Moir S, Hutcheon A, Heys S et al. (2004). Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. Breast Cancer Res 6: R601-R607.
11. Caraglia M, Giuberti G, Marra M, Di Gennaro E, Facchini G, Caponigro F et al. (2005). Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells. Front Biosci 10: 2566-2575.
12. Carmichael J, DeGraff W, Gazdar A, Minna J, Mitchell J. (1987). Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942.
13. Chang BD, Broude EV, Fang J, Kalinichenko TV, Abdryashitov R, Poole JC et al. (2000). p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells. Oncogene 19: 2165-2170.
14. Chen J-G, Yang C-PH, Cammer M, Band Horwitz S. (2003). Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 63: 7891-7899.
15. Consolini R, Pui C, Behm F, Raimondi S, Campana D. (1998). In vitro cytotoxicity of docetaxel in childhood acute leukemias. J Clin Oncol 16: 907-913.
16. Dieras V, Fumoleau P, Bourgeois H, Misset JL, Azli N, Pouillart P. (1996). Taxoids in combination chemotherapy for metastatic breast cancer. Anticancer Drugs 7(Suppl 2): 47-52.
17. Escuin D, Kline ER, Giannakakou P. (2005). Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1{alpha} accumulation and activity by disrupting microtubule function. Cancer Res 65: 9021-9028.
18. Fabbri F, Carloni S, Brigliadori G, Zoli W, Lapalombella R, Marini M. (2006). Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: A cytometric study. BMC Cell Biol 7: 6.
19. Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C et al. (1996). A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 7: 165-171.
20. Giannakakou P, Nakano M, Nicolaou KC, O'Brate A, Yu J, Blagosklonny MV et al. (2002). Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci USA 99: 10855-10860.
21. Giannakakou P, Robey R, Fojo T, Blagosklonny M. (2001). Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 20: 3806-3813.
22. Grandori C, Wu K-J, Fernandez P, Ngouenet C, Grim J, Clurman BE et al. (2003). Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev 17: 1569-1574.
23. Haldar S, Basu A, Croce C. (1997). Bcl2 is the guardian of microtubule integrity. Cancer Res 57: 229-233.
24. Hernández-Vargas H, Ballestar E, Carmona-Saez P, von Kobbe C, Bañón-Rodríguez I, Esteller M et al. (2006). Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int J Cancer 119: 1164-1175.
25. Jordan M, Wendell K, Gardiner S, Derry W, Copp H, Wilson L. (1996). Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816-825.
26. Li Y, Li X, Hussain M, Sarkar F. (2004). Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia 6: 158-167.
27. Mansilla S, Priebe W, Portugal J. (2006). Mitotic catastrophe results in cell death by caspase-dependentand caspase-independent mechanisms. Cell Cycle 5: 53-60.
28. Montero A, Fosella F, Hortobagyi GN, Valero V. (2005). Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6: 229-239.
29. Moreno-Bueno G, Sanchez-Estevez C, Cassia R, Rodriguez-Perales S, Diaz-Uriarte R, Dominguez O et al. (2003). Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 63: 5697-5702.
30. Morse DL, Gray H, Payne CM, Gillies RJ. (2005). Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 4: 1495-1504.
31. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. (2004). The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 3: 59-70.
32. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. (2002). The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-614.
33. Paoletti A, Giocanti N, Favaudon V, Bornens M. (1997). Pulse treatment of interphasic HeLa cells with nanomolar doses of docetaxel affects centrosome organization and leads to catastrophic exit of mitosis. J Cell Sci 110: 2403-2415.
34. Roninson IB, Broude EV, Chang B-D. (2001). If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Update 4: 303-313.
35. Stankiewicz AR, Lachapelle G, Foo CPZ, Radicioni SM, Mosser DD. (2005). Hsp70 inhibits heat-induced apoptosis upstream of mitochondria by preventing Bax translocation. J Biol Chem 280: 38729-38739.
36. Tarsounas M, Munoz P, Claas A, Smiraldo PG, Pittman DL, Blasco MA et al. (2004). Telomere maintenance requires the RAD51D recombination/repair protein. Cell 117: 337-347.
37. Torres K, Horwitz S. (1998). Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 58: 3620-3626.
38. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. (2005). Breast cancer. Lancet 365: 1727-1741.
39. von Kobbe C, May A, Grandori C, Bohr VA. (2004). Werner syndrome cells escape hydrogen peroxide-induced cell proliferation arrest. FASEB J 18: 1970-1972.
40. Wang Q, Wieder R. (2004). All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene 23: 426-433.
41. Yoo GH, Piechocki MP, Ensley JF, Nguyen T, Oliver J, Meng H et al. (2002). Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin Cancer Res 8: 3910-3921.
42. Zeng S, Chen YZ, Fu L, Johnson KR, Fan W. (2000). In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells. Clin Cancer Res 6: 3766-3773.